Written by Federico Citterich
Conceived and reviewed by Alessandro Rossetta
Despite the staggering ~€7 billion annual cost of pancreatic cancer in Europe, most of it stems from treating late-stage disease. Early detection could dramatically reduce both healthcare and productivity losses – transforming a medical challenge into an economic opportunity – but could also offer the chance to ease the profound social toll on patients and families.
So far we’ve only covered the medical importance of developing an early detection method for pancreatic cancer. However, late detection of pancreatic cancer and the need for highly specialized treatment also significantly increase the economic burden of the disease. Beyond the direct costs to healthcare systems, substantial indirect costs arise from prolonged work absences and premature exit from the labor market. As pancreatic cancer increasingly affects individuals during their productive years, it contributes to a notable loss in potential Gross Domestic Product (GDP). In the context of an aging population and shifting demographic structures across developed countries, maintaining a healthy, active workforce is critical – making early detection not only a medical priority but also an economic necessity.
THE ECONOMIC BURDEN OF PANCREATIC CANCER
Late-stage pancreatic cancer treatment is among the most expensive in oncology due to its complexity and intensity. Chemotherapy, palliative treatments, and hospitalization all increase the overall costs patients have to afford to get treated. Chemotherapy can cost up to €40,000 per patient, excluding supportive medication, and palliative treatments – including pain management, psychological support, and hospice care – become necessary early in the disease course, often for months, further driving costs.
However, the costs of pancreatic cancer don’t only translate in personal costs. In fact, indirect costs related to productivity loss are by far the largest share of the disease burden. Pancreatic cancer typically affects individuals aged 55–75, a demographic that includes many active workforce members and experienced professionals. The disease’s rapid progression and severe symptoms often result in immediate withdrawal from employment following diagnosis and/or long-term disability claims and early retirement, particularly in systems where returning to work is not feasible due to the severity of treatment side effects. Productivity losses per working patient are estimated at roughly between €150,000 and €250,000, accounting for ~70% of total costs. As survival is limited, there is no possibility of workforce reentry, resulting in permanent GDP loss.
The socioeconomic effect is even more pronounced in households where the patient is the primary earner or where caregivers (often women aged ~47) must leave the labor market to provide full-time care, causing a dual economic hit to families.
But treating pancreatic cancer also has significant costs for healthcare systems. In particular, the frequent hospital admissions needed for symptom control, diagnostic procedures (e.g., CT, MRI, PET scans, etc.), or surgical evaluations lead to additional costs. This is also coupled to the fact that advanced imaging and biopsy procedures are required not only for diagnosis but also for ongoing monitoring, increasing resource usage per patient.
Moreover, because the disease is usually detected at an advanced stage, surgical resection – the only curative option – is possible in fewer than 20% of patients. This leads to high usage of non-curative therapies, which prolong treatment timelines and resource utilization.
And it’s not to be forgotten that multidisciplinary teams are often involved in treating pancreatic cancer patients, including oncologists, gastroenterologists, radiologists, surgeons, palliative care teams, and sometimes social workers, further increasing costs.
In total, considering all the above aspects together, pancreatic cancer costs reach €7 billion per year in Europe.
SOCIAL IMPACT OF LATE DIAGNOSIS
But pancreatic cancer also inflicts a profound social toll that extends far beyond financial costs. Pancreatic cancer is often referred to as a “silent killer” because it is typically diagnosed at a late stage, when curative options are limited. By the time symptoms appear, the cancer is often already metastatic or locally advanced. According to multiple studies, the median survival time after diagnosis is around 4-6 months for late-stage pancreatic cancer patients. For many, diagnosis marks the beginning of a rapid decline, leaving little or no time to explore second opinions, alternative treatments, or experimental clinical trials. The compressed timeline places enormous emotional pressure on patients and families, who must navigate complex treatment decisions, financial planning, and end-of-life care in a matter of weeks. This sense of urgency and limited preparedness often results in fragmented care, rushed decision-making, and significant emotional trauma.
Additionally, significant disparities in access to timely diagnosis exist globally, contributing to unequal outcomes and late-stage detection particularly in under-resourced areas. Wealthier or more health-literate individuals are often better positioned to advocate for themselves, seek private diagnostics, or request specialist referrals earlier. In contrast, underserved populations—especially those in rural areas or lower socioeconomic brackets – face delayed referrals, limited access to imaging or specialists, and longer wait times. This creates a two-tiered diagnostic system: those with resources are more likely to detect disease earlier or access cutting-edge care, while others are left navigating late-stage disease with fewer options.
But the intense and rapid course of pancreatic cancer also profoundly affects family caregivers, often spouses or adult children. Studies show that over 60% of caregivers for terminal cancer patients suffer from high psychological distress, and pancreatic cancer caregivers report above-average levels of anxiety and depression. Many caregivers of pancreatic cancer patients experience “anticipatory grief” – the emotional strain of knowing the outcome is likely fatal, even before death occurs. Burnout is also common due to the physical intensity of caregiving tasks (feeding, hygiene, transport to appointments) and the emotional toll of witnessing a loved one’s rapid decline, and social isolation often occurs as caregivers often leave their jobs or reduce work hours, withdrawing from social activities and support systems.
POTENTIAL IMPACT OF EARLY DETECTION – WHO BENEFITS?
Imagine if we could detect pancreatic cancer before it became deadly and at a much lower cost – what would the ripple effects be? Recall that pancreatic cancer costs reach €7 billion per year in Europe. With early detection, treatment might only cost 20-30% of the current costs. As a result, early screening methods could save €3.5-4.5 billion per year on direct treatment.
Additionally, by preserving health in individuals aged 55–75 – peak working years – early detection also supports workforce retention. Lower rates of premature death and disability translate into reduced productivity losses and absenteeism, while social welfare systems experience less strain due to fewer disability claims, lower dependency, and delayed retirement. From a bigger perspective, governments and employers benefit from increased economic output and tax contributions from individuals who can continue working. The indirect costs saving could roughly be €1 billion per year.
By diagnosing the disease at an earlier, more treatable stage – particularly among high-risk groups such as individuals with new-onset diabetes or those with a family history – patients can also gain access to timely surgical interventions and potentially curative treatments. Surveillance programs, like MRI-based screening for high-risk cohorts, have already demonstrated a reduction in pancreatic cancer mortality and extended average life expectancy by over two years; early detection could hence improve quality of life by reducing symptom burden and avoiding aggressive, late-stage treatments. As a result, there would be an increase in the competitiveness of European society.
Beyond clinical outcomes, early detection alleviates the heavy emotional and logistical toll on caregivers by offering more time for decision-making and reducing the urgency and severity of interventions. Similarly, financial burden on families may be lowered due to fewer emergency interventions, less need for long-term care, and potentially shorter treatment timelines.
Healthcare systems also benefit from a shift toward prevention and early-stage management, avoiding the high costs associated with chemotherapy, hospitalization, and late-stage palliative care. In addition, an early diagnosis would enable a more strategic resource allocation, optimizing resource use.
REFERENCES
Cipora, E., Partyka, O., Pajewska, M., Czerw, A., Sygit, K., Sygit, M., … & Deptała, A. (2023). Treatment costs and social burden of pancreatic cancer. Cancers, 15(6), 1911.
https://www.mdpi.com/2072-6694/15/6/1911
Digestive Cancers Europe. (2021). The costs of pancreatic cancer.
Draus, T., Ansari, D., Wikström, F., Persson, U., & Andersson, R. (2021). Projected economic burden of pancreatic cancer in Sweden in 2030. Acta Oncologica, 60(7), 866-871.
https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1892821
Hernandez, D., Wagner, F., Hernandez-Villafuerte, K., & Schlander, M. (2023). Economic burden of pancreatic cancer in Europe: a literature review. Journal of Gastrointestinal Cancer, 54(2), 391-407.
https://link.springer.com/article/10.1007/s12029-022-00821-3
Johannssen, T. F. (2022). The survival benefit and cost-effectiveness of a pancreatic cancer early detection strategy for a targeted population of new-onset diabetes patients (Master’s thesis, University of Twente).
https://essay.utwente.nl/92991/
Kenner, B. J. (2018). Early detection of pancreatic cancer. Pancreas, 47(4), 363-367.
https://www.academia.edu/110262830/Early_detection_of_pancreatic_cancer
Wong, M. C., Jiang, J. Y., Liang, M., Fang, Y., Yeung, M. S., & Sung, J. J. (2017). Global temporal patterns of pancreatic cancer and association with socioeconomic development. Scientific reports, 7(1), 3165.
https://www.nature.com/articles/s41598-017-02997-2